跳至主要内容
临床试验/CTRI/2022/07/043917
CTRI/2022/07/043917尚未招募4 期

Prospective Analysis of safety, effectiveness and compliance of EPO (erythropoietin) therapy by using WEPOX® Dispopen 20,000 IU, A new delivery device, in the management of CKD Anemia - AWAKE

Wockhardt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • Patients newly prescribed with WEPOX Dispopen 20000 IU for anemia due to chronic kidney disease (CKD)
  • Patient willing to comply with the protocol and written Informed Consent

排除标准

  • Patients who do not meet requirement as per prescribing information of WEPOX Dispopen 20000 IU
  • Pregnant and lactating females

研究者

发起方
Wockhardt Ltd

相似试验